Image source: Getty Images.
It has been a tough year to be a Gilead Sciences (NASDAQ: GILD) shareholder. Fears of incoming competition for the company’s hepatitis C virus (HCV) treatments have been exacerbated by declining sales among its HCV drug-based treatments.